Brian is a partner in the Corporate & Securities practice and a member of the Life Sciences industry team. He works with public and private companies on securities, corporate finance, and corporate governance matters. He also advises in connection with structuring, negotiating, and completing mergers, acquisitions, divestitures, licenses, collaboration agreements, and joint ventures. As a trusted professional, Brian guides clients through SEC reporting and compliance including Section 13 and Section 16 obligations, Rule 144 matters, preparation of ’34 Act reports, NYSE and NASDAQ rules compliance, proxy statements, and general disclosure obligations under the federal securities laws. He also works with issuers in securities and corporate finance transactions, including registered offerings, private offerings (including Reg D, Rule 144A and Reg A+ offerings), consent solicitations, and tender and exchange offers involving debt and equity securities. When helping companies in corporate governance matters, Brian advises on board of directors’ duties, executive compensation, board and shareholder meetings, and administration of compensation/equity plans. In his legal practice, Brian draws from the business acumen gained from his time as in-house counsel for an Atlanta-based publicly traded life sciences company. A significant portion of his practice involves the representation of companies and investors in the healthcare and life sciences industries in transactions involving companies at all stages of the corporate life cycle.